Oren Gilad, President/CEO at Aprea Therapeutics, Inc. (APRE), bought 500 shares at $3.92 ($2K) on 2024-10-23, disclosed to the SEC on 2024-10-24.
Open-market purchase of $2k APRE by President/CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| APRE | BUY | 2024-10-16 | $725 | — | Filing → |
| APRE | BUY | 2024-10-15 | $3K | — | Filing → |
| APRE | BUY | 2024-03-14 | $15K | — | Filing → |